165.47 +0.26 (0.16%)
After hours: 4:11PM EDT
|Bid||126.12 x 100|
|Ask||175.10 x 100|
|Day's Range||164.55 - 168.34|
|52 Week Range||134.19 - 181.72|
|PE Ratio (TTM)||13.53|
|Earnings Date||Apr 25, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||193.50|
Labcorp's (LH) multi-year LaunchPad project holds enough promise for growth. Good news is that the company already grossed savings worth $20 million from the same in 2017.
BUFFALO, N.Y., April 12, 2018-- OmniSeq ®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation’ s participation in ...
LabCorp has officially announced its expansion into new space at the former GlaxoSmithKline space in Research Triangle Park and the new jobs that will come with it.
LabCorp® announced today that its Zero Coupon Convertible Subordinated Notes due 2021 may be converted as set forth below.
A lawsuit has been filed alleging that LabCorp has violated the Telephone Consumer Protection Act by making automated phone calls.
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
Through the partnership, LabCorp will offer a range of services, including technical services for Appalachian Regional's hospital-based labs.
LabCorp® and Appalachian Regional Healthcare have entered into a multi-year, comprehensive laboratory partnership. Through the collaboration, LabCorp Diagnostics will provide technical services for Appalachian Regional Healthcare’s hospital-based labs, reference testing services for its entire network of facilities and clinicians, and access to enhanced information technology and data analytics to ...
Per the new deal with Interpace, Dianon Pathology, member of the LabCorp (LH) Specialty Testing Group, is supposed to perform the thyroid biopsy analysis.
NEW YORK, March 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
PARSIPPANY, N.J., March 20, 2018-- Interpace Diagnostics Group, Inc., a fully integrated commercial and bioinformatics company that provides clinically useful molecular diagnostic tests and pathology services ...
Theranos and two of its principal officers were charged by the SEC with an "elaborate, years-long fraud" that raised $700 million for the needles-free blood diagnostics company that once was the toast of the media and investment world.
A business unit of Laboratory Corporation of America Holdings has created a division to focus on offerings to help further the development of biologic drugs, the Burlington-based company said. The creation of the immunology and immunotoxicology unit by Covance Drug Development comes as LabCorp has focused on expanding its operations beyond laboratory diagnostics in order to become a global life sciences company. LabCorp (LH) acquired Covance for $6.2 billion in 2015.
The creation of the immunology and immunotoxicology unit by Covance Drug Development comes as LabCorp has focused on expanding its operations beyond laboratory diagnostics in order to become a global life sciences company.
LabCorp® announced today that for the period of March 12, 2018 to September 11, 2018, its Zero Coupon Convertible Subordinated Notes due 2021 will accrue contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 9, 2018, in addition to the continued accrual of the original issue discount.
Almost a year after acquiring Pathology Associates Medical Laboratories, LabCorp will lay off about 195 employees with the Spokane, Washington-based company. The layoffs, which will take place in the next several months, will only occur in Spokane. Once complete, the company will have about 500 employees in the area, said Don Von Hagen, spokesperson for Laboratory Corporation of America Holdings (LH).
LabCorp® , a leading global life sciences company, announced today that its Covance Drug Development business has formed a global immunology and immunotoxicology unit dedicated to the specific needs of biologic drug development.